ArticleAntimicrobial agents and chemotherapy1999
Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice.
Article in Antimicrobial agents and chemotherapy, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Advancing Tuberculosis Treatment with Next-Generation Drugs and Smart Delivery Systems.Pharmaceutics · 2026Review
- PLGA Carriers for Controlled Release of Levofloxacin in Anti-Tuberculosis Therapy.Pharmaceutics · 2022Article
- Induction of autophagy through CLEC4E in combination with TLR4: an innovative strategy to restrict the survival ofAutophagy · 2020Article
- Gentamicin-Loaded Chitosan Nanoparticles Improve Its Therapeutic Effects onGalen medical journal · 2019Article
- The Synergistic Effect of Exogenous Glutamine and Rifampicin AgainstFrontiers in microbiology · 2018Article
- Preparation and characterization of beta-glucan particles containing a payload of nanoembedded rifabutin for enhanced targeted delivery to macrophages.EXCLI journal · 2017Article
- 25-Hydroxyvitamin D(3)-loaded PLA microspheres: in vitro characterization and application in diabetic periodontitis models.AAPS PharmSciTech · 2013Article
- Characterization, activity, and computer modeling of a molecular inclusion complex containing rifaldazine.International journal of nanomedicine · 2013Article
- Formation of inhalable rifampicin-poly(L-lactide) microparticles by supercritical anti-solvent process.AAPS PharmSciTech · 2008Article
- Effect of different oral doses of isoniazid-rifampicin in rats.Molecular and cellular biochemistry · 2006Article
- Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis.Pharmaceutical research · 2001Article
- Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model.Pharmaceutical research · 2001Article
- Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid.Antimicrobial agents and chemotherapy · 2001Article
- Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.Antimicrobial agents and chemotherapy · 2001Article
- Preparation, in vitro characterization, and in vivo pharmacokinetic evaluation of respirable porous microparticles containing rifampicin.Scientia pharmaceuticaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rifampin is a first-line drug useful in the treatment of tuberculosis. By using biocompatible polymeric excipients of lactide and glycolide copolymers, two microsphere formulations were developed for targeted and sustained delivery of rifampin, with minimal dosing. A small-microsphere formulation, with demonstrated ability to inhibit intracellularly replicating Mycobacterium tuberculosis H37Rv, was tested along with a large-microsphere formulation in an infected mouse model. Results revealed that by using a single treatment of the large-microsphere formulation, it was possible to achieve a significant reduction in M. tuberculosis H37Rv CFUs in the lungs of mice by 26 days postinfection. A combination of small (given as two injections on day 0 and day 7) and large (given as one injection at day 0) rifampin-loaded microsphere formulations resulted in significant reductions in CFUs in the lungs by 26 days, achieving a 1.23 log10 reduction in CFUs. By comparison, oral treatment with 5, 10, or 20 mg of rifampin/kg of body weight, administered every day, resulted in a reduction of 0.42, 1.7, or 1.8 log10 units, respectively. Thus the microsphere formulations, administered in one or two doses, were able to achieve results in mice similar to those obtained with a daily drug regimen within the range of the highest clinically tolerated dosage in humans. These results demonstrate that microsphere formulations of antimycobacterial drugs such as rifampin can be used for therapy of tuberculosis with minimal dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.